Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16465393 | 0.88 | LIPG (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL13860602 | 0.85 | FFAR1 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22655326 | 0.84 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL506556 | 0.83 | ESR2 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL505948 | 0.83 | LPL (0.40) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL506042 | 0.83 | LIPG (0.40) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22655354 | 0.83 | CA1 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22655298 | 0.83 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19521353 | 0.82 | FFAR1 (0.43) | LPLLIPGF11FFAR1F2 | |
| SCHEMBL22558742 | 0.82 | LPL (0.43) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600717-B2 | Tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-20240417392-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2024-12-19 | — | — | US | disclosed |
| CN-118894816-A | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-11-05 | — | — | CN | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-12110279-B2 | Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2024-10-08 | — | — | US | disclosed |
| US-12053473-B2 | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-06 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2751093-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140100214-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| EP-2569313-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011143426-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600717-B2 | Tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | LPL 4192/4885LIPG 4098/4885CA1 2745/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | LPL 1930/4885LIPG 1091/4885CA1 2993/4885 |
| US-12110279-B2 | Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same | VAPB, VAPA, FABP1 | LPL 439/4885LIPG 762/4885CA1 4801/4885 |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | LPL 4640/4885LIPG 3962/4885CA1 4196/4885 |
| US-20140100214-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | LPL 1930/4885LIPG 1091/4885CA1 2993/4885 |
| US-20240417392-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPA, VAPB, SLC10A1 | LPL 361/4885LIPG 1014/4885CA1 4788/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | LPL 4583/4885LIPG 3800/4885CA1 1467/4885 |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | LPL 3435/4885LIPG 2499/4885CA1 3781/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | LPL 4054/4885LIPG 3519/4885CA1 3900/4885 |
| US-12053473-B2 | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors | SOS1, SOS2, SOST | LPL 4877/4885LIPG 4795/4885CA1 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.